Logo

Seattle Genetics and Astellas Collaborate with Merck to Evaluate Enfortumab Vedotin + Keytruda (pembrolizumab) for Metastatic Urothelial Cancer

Share this
Seattle Genetics and Astellas Collaborate with Merck to Evaluate Enfortumab Vedotin + Keytruda (pembrolizumab) for Metastatic Urothelial Cancer

Seattle Genetics and Astellas Collaborate with Merck to Evaluate Enfortumab Vedotin + Keytruda (pembrolizumab) for Metastatic Urothelial Cancer

Shots:

  • Seattle Genetics and Astellas sign a clinical trial agreement with Merck to evaluate the combination of Seattle Genetics’ and Astellas’ ADC and Merck’s anti-PD-1 therapy in patients with previously untreated metastatic urothelial cancer
  • The three companies will conduct and fund P-III study to be led by Seattle Genetics and will work with regulatory authorities to finalize the trial design with the expected onset of the study in H1’20
  • Enfortumab Vedotin is an investigational ADC comprising of an anti-Nectin-4 mAb- attached to a MMAE utilizing Seattle Genetics' technology and has received FDA’s BT designation in Mar’2018 with its PDUFA date as Mar 15- 2020

Click here to­ read full press release/ article 

Ref: Astellas | Image: Merck 


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions